Adolor 8-K 2005
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) April 19, 2005
(Exact name of registrant as specified in its charter)
Registrants telephone number, including area code: (484) 595-1500
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Item 8.01. Other Events.
On April 19, 2005, Adolor Corporation (the Company) announced that the U. S. Food and Drug Administration has extended the Prescription Drug User Fee Act target action date from April 25, 2005 to July 25, 2005 for the completion of its review of the Companys New Drug Application for Entereg (alvimopan) capsules for the management of postoperative ileus. The press release issued by the Company concerning the announcement is attached to this Report as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits
99.1 Press Release of the Company, dated April 19, 2005.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
Dated: April 20, 2005